MaxCyte now expects full year 2024 core business revenue of at least 5% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback